Although strong evidences of the benefit of H2R antagonists on the prevention of anaphylaxis reactions are lacking (20), the EAACI guidelines recommended them as third-line treatment (21) based on their capacity to improve cutaneous symptoms (22, 23). The gene discussed is HRH2; the disease is anaphylaxis.